

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jason D. Bonk *et al.*
Serial No.: 10/596,897
Confirmation No.: 1956
Filed: June 28, 2006
For: IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL, AND
IMIDAZONAPHTHYRIDINYL SULFONAMIDES
Examiner: R. J. Desai
Art Unit: 1625

Certificate of Electronic Filing Under 37 CFR 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: July 15, 2009

Signature: /Heather A. McLennand/

(Heather A. McLennand)

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Madam:

In response to the restriction requirement set forth in the Office Action mailed June 19, 2009, Applicant hereby elects Group I (claims 2-6, 10, 12, 14-16, 18, 20-21, 23-25, 35-54, 59, 61, 63 and 65), drawn to compounds of the formula Ia where R_A and R_B together form a six-membered carbocyclic ring, X is not interrupted by an O, and R₁ and R₁' are H, alkyl, alkyl aryl, cycloalkyl or combined to form a morpholine or piperidine, and compositions thereof, for prosecution in the present application. Furthermore, Applicant elects the compound of Example 4 on page 100 as the species for search purposes. The claims encompassing the elected species include claims 2, 4, 5-6, 12, 14-16, 18, 20-21, 23-25, 39-54, 61, 63, and 65.

The Examiner states that Group I includes claims 2-6, 10, 12, 14-16, 18, 20-21, 23-25, 35-54, 59, 61, 63, and 65. Applicant respectfully points out that independent claim 3 and dependent

claims 10, 35-38, and 59 do not fall within the scope of Group I as described. Consequently, Group I encompasses claims 2, 4, 5-6, 12, 14-16, 18, 20-21, 23-25, 39-54, 61, 63, and 65.

Having made the election, Applicant expressly reserves the right to pursue the subject matter of the non-elected claims in one or more future applications claiming priority to the present application.

Applicant believes no fee is due with this response. If there is a fee occasioned by this response that is not covered, please charge any deficiency to Deposit Account No. 23/2825, under Docket No. C1271.70045US03, from which the undersigned is authorized to draw.

Dated: July 15, 2009

Respectfully submitted,

By /C. Hunter Baker/
C. Hunter Baker, M.D., Ph.D.
Registration No.: 46,533
WOLF, GREENFIELD & SACKS, P.C.
Federal Reserve Plaza
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
617.646.8000